Integrilin encourages faster reperfusion
Integrilin encourages faster reperfusion
When added to the thrombolytic protocol, Integrilin, a platelet aggregation inhibitor, encourages faster and more frequent reperfusion for thrombolytic patients with acute myocardial infarction, according to E. Magnus Ohman, MD, a researcher at Duke University.
Ohman and fellow researchers tested the effectiveness of Integrilin in a randomized, double-blind trial of 132 patients with thrombolysis. All patients in the study were given accelerated alteplase, aspirin, and intravenous heparin infusion. Compared with patients in the placebo group, those given Integrilin had more complete reperfusion and recovered more quickly. Results were published in the Feb. 18 issue of Circulation.
"[These data] are the first to show that dissolving blood clots with alteplase and keeping them from reforming with this new type of drug restores blood flow faster in heart attack patients than just giving the clot dissolver alone," Ohman said in a statement released by the American Heart Association.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.